

Title: Impacting Type 2 Diabetes and Optimizing Patient Outcomes with GLP-1 Receptor Agonists
Dates: September 18, 2013 – September 18, 2014
Locations: Online: http://www.medscape.org/viewarticle/809760_2

Learning Objectives

After completing this activity, the participant should be better able to:

- Design pharmacologic strategies that optimize the use of GLP-1 receptor agonist therapy in comprehensive care plans for patients with diabetes based on stage of disease
- Select glucose-lowering strategies based on patient factors that affect treatment success and patient safety
- Summarize current and future trends of GLP-1 receptor agonist-based treatment strategies based on scientific and clinical evidence that address current unmet needs

Target Audience

This activity was developed for endocrinologists, internists, primary care clinicians, and other healthcare professionals who manage patients with type 2 diabetes.

Program Overview

Management of type 2 diabetes is shifting to new treatment modalities that offer low risks of hypoglycemia and weight gain while effectively lowering blood glucose levels. GLP-1 receptor agonists can be used alone or in combination with other agents. This case-based continuing education program will explore the relative merits of GLP-1 receptor agonist therapy across the spectrum of patients with type 2 diabetes and provide a pathophysiologic and clinical rationale for the use of these agents. Faculty will present complex cases and review the rationale for and against different therapeutic options, and present data supporting why GLP-1 receptor agonists might be appropriate as part of mono- or combination-therapy strategies. Clinical scenarios and patient complexities that may require physicians to reconsider, re-evaluate, adjust therapy, or re-affirm their clinical decisions will be posed to the faculty for their expert opinions.

Faculty

Vivian Fonseca, MD, FACE, Moderator
Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Lawrence Blonde, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes, and Metabolic Diseases
Ochsner Medical Center
New Orleans, Louisiana

Michael A. Nauck,
Professor and Head Physician
Diabeteszentrum Bad Lauterberg
Harz, Germany

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Clinical and Patient Educators Association (CPEA) and Global Directions in Medicine. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Clinical and Patient Educators Association designates this enduring material for a maximum of 2.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

CPEA requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support

This activity is supported by an educational grant from Novo Nordisk, Inc.